Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis

Trial Profile

Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rabeprazole (Primary)
  • Indications Reflux oesophagitis
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 13 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 16 Dec 2014 Planned End Date changed from 1 Mar 2013 to 1 Mar 2015 according to ClinicalTrials.gov record.
    • 16 Dec 2014 Planned primary completion date changed from 1 Mar 2013 to 1 Mar 2015 according to ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top